Unraveling the WISDOM Trial: A Controversial Take on Breast Cancer Screening
The Society of Breast Imaging (SBI) has recently voiced concerns about the Women Informed to Screen Depending on Measures of Risk (WISDOM) trial, a study that aimed to explore risk-based breast cancer screening. The trial's findings, published in JAMA, have sparked a debate within the medical community.
Methodological Flaws and Uncertainty
SBI argues that the trial's conclusions are unsupported due to significant methodological issues. They highlight that it remains unclear whether risk-based screening can be effectively implemented on a population-wide scale. Let's delve into the specific concerns raised:
Randomization Refusal: A significant number of women, approximately 40%, opted out of randomization and joined an observational cohort. SBI questions the reasons behind this large-scale refusal and the decision to allow participants to decline randomization.
Underpowered Study: The trial enrolled far fewer women than expected, which limits its ability to detect meaningful differences in cancer rates. With only 28,372 women enrolled, the study's power is compromised.
Low Cancer Rates: The overall number of cancers detected was low, with just 21 cases in the risk-based screening cohort and 31 in the annual mammogram group. This outcome suggests that the study lacked the statistical strength to support its proposed conclusions.
Stage of Cancer Detection: The study focused on stage ≥ IIB breast cancers, which are often clinically detectable. SBI emphasizes that annual screening detects cancers at earlier, non-palpable stages, and the exclusion of these earlier-stage cancers undermines the critical benefit of screening mammography.
Contamination and Noncompliance: SBI reports substantial contamination and noncompliance within the randomized cohorts, further compromising the trial's integrity.
Biopsy Rates: Risk-based screening led to more biopsies compared to annual screening, although the difference was not statistically significant. This indicates that risk-based screening did not reduce the need for percutaneous needle biopsies.
Self-Reporting Bias: The study relied on patient self-reporting for cancer, biopsy, and imaging data. SBI considers self-reporting an unreliable source of information, especially given the study population's demographic bias towards college-educated white women, making the results less generalizable.
A Step Towards Personalized Screening?
Despite these criticisms, SBI acknowledges that the risk-based screening cohort received counseling on risk-reducing strategies. However, adherence to these strategies was poor, even with this intervention.
Ultimately, while risk-based breast cancer screening holds promise for personalized regimens and efficient resource allocation, the WISDOM trial's flaws and limitations prevent it from providing a reliable pathway for systematic implementation. SBI continues to recommend annual mammogram screening starting at age 40 for all women at average risk, as this approach has been shown to confer the greatest mortality benefit.
And this is where the controversy lies: Should we embrace risk-based screening despite its challenges, or is the traditional annual mammogram still the gold standard? What are your thoughts on this complex issue? Feel free to share your opinions and engage in a constructive discussion in the comments below!
